The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...
By Nikhil Sharma (Reuters) -European shares reached a record high on Friday, led by technology and healthcare stocks, as ...
Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Novartis Ag (NYSE: NVS) Q4 2024 Earnings Call Jan 31, 2025, 8:00 a.m. ET ...
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. | To direct more attention toward the importance of ...
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback